Jointown Pharmaceutical Group Co (SHSE:600998) Piotroski F-Score: 4 (As of Sep. 13, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600998 Jointown Pharmaceutical Group Co Ltd SHSE:600998
83 GF Score
Price ¥4.97
GF Value ¥5.49
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Jointown Pharmaceutical Group Co Piotroski F-Score?

Jointown Pharmaceutical Group Co SHSE:600998 -1.39% 83 Piotroski F-Score is 4 as of Sep. 13, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates SHSE:600998 with a GF Score™ of 83/100 and a GF Value™ of ¥5.49 (Fairly Valued). The stock has 6 warning signs investors should review. Among 116 Medical Distribution companies, Jointown Pharmaceutical Group Co ranks worse than 57.76% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jointown Pharmaceutical Group Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Jointown Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:600998' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Jointown Pharmaceutical Group Co was 8. The lowest was 3. And the median was 6.

Jointown Pharmaceutical Group Co  (SHSE:600998) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jointown Pharmaceutical Group Co Piotroski F-Score Related Terms


Jointown Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Jointown Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jointown Pharmaceutical Group Co Piotroski F-Score Chart

Jointown Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 6.00 7.00 3.00

Jointown Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 3.00 3.00 4.00

SHSE:600998 vs MCK, COR, CAH: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Jointown Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jointown Pharmaceutical Group Co Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Jointown Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jointown Pharmaceutical Group Co's Piotroski F-Score falls into.


SHSE:600998
83GF Score
Jointown Pharmaceutical Group Co Ltd SHSE:600998
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 529.891 + 279.414 + 733.16 + 467.406 = ¥2,010 Mil.
Cash Flow from Operations was 504.195 + 5757.215 + -3023.511 + 242.749 = ¥3,481 Mil.
Revenue was 38220.367 + 42063.421 + 44782.649 + 42496.612 = ¥167,563 Mil.
Gross Profit was 3128.053 + 3287.67 + 3342.854 + 3441.182 = ¥13,200 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(107773.769 + 112278.352 + 116407.434 + 121724.367 + 120775.272) / 5 = ¥115791.8388 Mil.
Total Assets at the begining of this year (Jun25) was ¥107,774 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,979 Mil.
Total Current Assets was ¥99,623 Mil.
Total Current Liabilities was ¥79,874 Mil.
Net Income was 488.549 + 811.205 + 969.855 + 475.703 = ¥2,745 Mil.

Revenue was 36258.173 + 38380.748 + 42016.176 + 39090.028 = ¥155,745 Mil.
Gross Profit was 2923.596 + 2808.806 + 3080.152 + 3053.69 = ¥11,866 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(98704.644 + 101016.64 + 102395.868 + 108880.056 + 107773.769) / 5 = ¥103754.1954 Mil.
Total Assets at the begining of last year (Jun24) was ¥98,705 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,796 Mil.
Total Current Assets was ¥88,501 Mil.
Total Current Liabilities was ¥70,707 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jointown Pharmaceutical Group Co's current Net Income (TTM) was 2,010. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jointown Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 3,481. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=2009.871/107773.769
=0.01864898

ROA (Last Year)=Net Income/Total Assets (Jun24)
=2745.312/98704.644
=0.0278134

Jointown Pharmaceutical Group Co's return on assets of this year was 0.01864898. Jointown Pharmaceutical Group Co's return on assets of last year was 0.0278134. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jointown Pharmaceutical Group Co's current Net Income (TTM) was 2,010. Jointown Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 3,481. ==> 3,481 > 2,010 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=2979.299/115791.8388
=0.02572978

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=1796.296/103754.1954
=0.017313

Jointown Pharmaceutical Group Co's gearing of this year was 0.02572978. Jointown Pharmaceutical Group Co's gearing of last year was 0.017313. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=99622.619/79874.216
=1.24724378

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=88501.247/70707.322
=1.25165604

Jointown Pharmaceutical Group Co's current ratio of this year was 1.24724378. Jointown Pharmaceutical Group Co's current ratio of last year was 1.25165604. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jointown Pharmaceutical Group Co's number of shares in issue this year was 5202.847. Jointown Pharmaceutical Group Co's number of shares in issue last year was 4864.866. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=13199.759/167563.049
=0.07877488

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11866.244/155745.125
=0.07619015

Jointown Pharmaceutical Group Co's gross margin of this year was 0.07877488. Jointown Pharmaceutical Group Co's gross margin of last year was 0.07619015. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=167563.049/107773.769
=1.55476653

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=155745.125/98704.644
=1.57789055

Jointown Pharmaceutical Group Co's asset turnover of this year was 1.55476653. Jointown Pharmaceutical Group Co's asset turnover of last year was 1.57789055. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jointown Pharmaceutical Group Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Jointown Pharmaceutical Group Co (SHSE:600998) has a Piotroski F-Score of 4 as of Sep. 13, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jointown Pharmaceutical Group Co and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Jointown Pharmaceutical Group Co's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Jointown Pharmaceutical Group Co ranks #67 out of 116 companies in the Medical Distribution industry, placing it in the top 57.8%.
Is Jointown Pharmaceutical Group Co's Piotroski F-Score too high?
Jointown Pharmaceutical Group Co's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Jointown Pharmaceutical Group Co's value of 4 is 20% below this industry median. Based on the distribution chart, Jointown Pharmaceutical Group Co ranks #67 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Jointown Pharmaceutical Group Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jointown Pharmaceutical Group Co's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Jointown Pharmaceutical Group Co ranks #67 out of 116 companies for Piotroski F-Score. This places Jointown Pharmaceutical Group Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Jointown Pharmaceutical Group Co's value of 4 is 20% below this benchmark. Historically, Jointown Pharmaceutical Group Co's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Jointown Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jointown Pharmaceutical Group Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jointown Pharmaceutical Group Co and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jointown Pharmaceutical Group Co's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jointown Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jointown Pharmaceutical Group Co (SHSE:600998) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.49, compared to a current price of ¥4.97 — trading 9.5% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Medical Distribution industry median of 5.00. Jointown Pharmaceutical Group Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jointown Pharmaceutical Group Co (SHSE:600998), the current Piotroski F-Score is 4 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jointown Pharmaceutical Group Co (SHSE:600998) Overvalued in 2026?

Based on GuruFocus' analysis, Jointown Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥4.97 is trading 9.5% below its estimated GF Value™ of ¥5.49. GuruFocus considers Jointown Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600998:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: ¥5.49 vs. price of ¥4.97 (9.5% below fair value)
  • GF Score™: 83/100 with 6 warning signs
  • Industry Position: 20% below the Medical Distribution median (#67 of 116)

No single metric tells the full story. See the SHSE:600998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jointown Pharmaceutical Group Co Business Description

Address No. 5, Longxing West Street, Hanyang District, Hubei Province, Wuhan, CHN, 430051
Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and mainly serves medical institutions, wholesale enterprises, and retail pharmacies.
83GF Score

Get the complete analysis for SHSE:600998

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.97
Price
¥5.49
GF Value